Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3/7/25 20:17 | 3/7/25 | BGNE | Health | Drug | Pharmaceutical Preparations | Oyler John | E9 | DO | CEO | 3 | S.d | -49,665 | 248.70 | 0 | -200 | 0 | 51,656 | D | ||||||||||||||
3/7/25 19:24 | 3/5/25 | BGNE | Health | Drug | Pharmaceutical Preparations | Wu Xiaobin | E9 | O | P,COO,GM | 3 | S.dm | -26,067 | 251.03 | 0 | -104 | 1,192 | D | |||||||||||||||
3/6/25 16:48 | 3/4/25 | BGNE | Health | Drug | Pharmaceutical Preparations | Wang Xiaodong | E9 | DH | Chair, S | 3 | S.d | -18,869 | 205.85 | 0 | -92 | 10,325 | I | |||||||||||||||
3/3/25 16:49 | 2/27/25 | BGNE | Health | Drug | Pharmaceutical Preparations | Lee Chan Henry | E9 | O | SVP,GC | 2 | S | -642 | 266.53 | 0 | -2 | 222 | D | |||||||||||||||
2/28/25 21:28 | 2/28/25 | ONC | Health | Drug | Pharmaceutical Preparations | Baker Bros. Advisors LP | NY | D | 1 | S | -190,535 | 260.00 | 0 | -733 | 8,341 | I | ||||||||||||||||
2/25/25 17:06 | 2/21/25 | BGNE | Health | Drug | Pharmaceutical Preparations | Wang Lai | E9 | O | Global H | 1 | S | -1,286 | 257.23 | 0 | -5 | 0 | 1,653 | I |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |